MedTrace Logo

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

NCT00667810 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 901

Last updated 2016-01-08

Study results available
· View outcomes & findings →

Summary

This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

Conditions

  • Alzheimer Disease

Interventions

DRUG

bapineuzumab

Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.

DRUG

bapineuzumab

Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.

DRUG

placebo

Placebo will be administered by IV infusion approximately every 13 weeks through week 65.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-10-31
Completion
2013-08-31

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Canada
  • Chile
  • Croatia
  • Finland
  • France
  • Germany
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • New Zealand
  • Poland
  • Portugal
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667810 on ClinicalTrials.gov